Abstract
Objective There are few reports on the outcomes of 12-week paritaprevir, ombitasvir, and ritonavir (PTV/OBV/r) treatment in real-world clinical settings. We aimed to evaluate the efficacy and safety of 12-week treatment with ritonavir-boosted paritaprevir and ombitasvir in patients with hepatitis C virus (HCV) genotype 1 infection in a real-world setting. Methods Fifty-eight patients with chronic hepatitis or compensated hepatic cirrhosis and genotype-1 HCV infection were treated with PTV/OBV/r and followed for 24 weeks after the completion of treatment in 10 centers in northern Tohoku. The efficacy and safety of this 12-week treatment regimen was analyzed. Results Among the 58 treated patients, 18 (31%) had compensated liver cirrhosis, while 11 (19%) patients had experienced treatment failure with another treatment regimen. NS5A resistance-associated variants (RAVs) were detected at baseline in 3 patients (5.2%), including Y93H in two patients and L31M in two patients. One patient had NS5A RAVs at both positions 93 and 31. The overall sustained virological response (SVR) 24 rate was 96.6%. Three patients with NS5A RAVs also achieved an SVR24. The SVR24 rate was not significantly affected by age, sex, prior treatment, prior his...Continue Reading
References
May 1, 1992·Virology·H OkamotoS Mishiro
Oct 1, 1990·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K KiyosawaR H Purcell
Feb 1, 1994·Digestive Diseases and Sciences·M YamadaM Takayanagi
Mar 22, 1997·Lancet·T PoynardP Opolon
Feb 12, 1998·Annals of Internal Medicine·P MarcellinS Erlinger
Nov 26, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·C NiederauD Häussinger
Mar 29, 2002·The Annals of Pharmacotherapy·R Chris Rathbun, Deanna R Rossi
Jan 30, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Masahiko KodaYoshikazu Murawaki
Jun 15, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anaïs Vallet-PichardStanislas Pol
Nov 6, 2012·Journal of Virological Methods·Kenichi TadokoroHiromitsu Kumada
Mar 8, 2014·Journal of Gastroenterology·Takeo ToshimaYoshihiko Maehara
Nov 15, 2014·PloS One·Yoshihito UchidaSatoshi Mochida
Feb 4, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kazuaki ChayamaHiromitsu Kumada
Apr 24, 2015·Journal of Gastroenterology·Toshiki KanKentaro Yoshioka
Jun 14, 2015·Journal of Hepatology·Amit KhatriSandeep Dutta
Jul 7, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hiromitsu KumadaRebecca Redman
Jul 15, 2015·Gastroenterology·Eric LawitzChristophe Hézode
Dec 9, 2015·Antimicrobial Agents and Chemotherapy·Preethi KrishnanTami Pilot-Matias
Apr 17, 2016·Advances in Therapy·Sathej GopalakrishnanJiuhong Zha
Jan 17, 2017·The Tohoku Journal of Experimental Medicine·Ken SatoMasanobu Yamada
May 1, 2017·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Masanori AtsukawaKatsuhiko Iwakiri